<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="200">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00212381</url>
  </required_header>
  <id_info>
    <org_study_id>9218</org_study_id>
    <nct_id>NCT00212381</nct_id>
    <nct_alias>NCT00206804</nct_alias>
  </id_info>
  <brief_title>Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia</brief_title>
  <official_title>Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Presbyterian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Presbyterian Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the use of oral Diindolylmethante (DIM), a marketed cruciferous vegetable
      based dietary supplement (Bioresponse-DIM), is associated with the regression of cervical
      dysplasia in otherwise healthy women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine if the use of oral Diindolylmethane (DIM), a marketed cruciferous vegetable
      based dietary supplement (BioResponse-DIMÂ®), is associated with the regression of cervical
      dysplasia in otherwise healthy women. Additionally, the study aims to see how the use of the
      BioResponse-DIM supplement correlates with cervical HPV colonization, and to asses the
      tolerability of daily DIM supplementation
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2000</start_date>
  <completion_date>August 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To determine if oral DIM is effective in promoting the regression of CIN in women</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To correlate the response to DIM with HPV colonization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess for any adverse effects of oral DIM in women</measure>
  </secondary_outcome>
  <enrollment>62</enrollment>
  <condition>Cervical Dysplasia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diindolylmethane (DIM)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non pregnant women greater than or equal to 18 years of age able to consent

          -  CIN II or III confirmed by histology

          -  Karnofsky performance status &gt;= 80

          -  No prior treatment for dysplasia in the past 4 months

        Exclusion Criteria:

          -  Incompletely visible lesion

          -  Diethylstilbestrol (DES) exposure

          -  HIV seropositive
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Del Priore, M.D., M.P.H.</last_name>
    <role>Study Director</role>
    <affiliation>NY Downtown Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Arslan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roopa R Chakkappan, M.P.H</last_name>
    <phone>212-312-5268</phone>
    <email>roopa.chakkappan@downtownhospital.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Arslan, M.D.</last_name>
      <phone>212-263-7792</phone>
      <email>akhmea01@popmail.med.nyu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Giuseppe Del Priore, M.D, M.P.H.</last_name>
      <phone>212-312-5268</phone>
      <email>giuseppe.delpriore@downtownhospital.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <lastchanged_date>September 13, 2005</lastchanged_date>
  <firstreceived_date>September 13, 2005</firstreceived_date>
  <keyword>cervical dysplasia, diindolylmethane, pap smear</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
